[LDL apheresis using a double filtration technique. Results after a 6-to-12 month follow-up in patients with refractory hyperlipemia and ischemic heart disease].
Five patients with a family history of hypercholesterolemia were treated for one year with double filtered technique of LDL-apheresis: heterozygotic in four patient and homozygotic in one. All patients presented documented cardiovascular disease and had been treated unsuccessfully with lipid lowering drugs. Plasmatic cholesterol was significantly reduced from 463.8 +/- 60.9 mg/dl to 326.36 +/- 36 mg/dl at 6 months after treatment and 347.56 +/- 68.1 mg/dl at 12 months (p < 0.05). LDL was also reduced from 407.92 +/- 69.39 mg/dl to 294.04 +/- 62.02 mg/dl and 296.6 +/- 82.42 mg/dl respectively (p < 0.05) and Apo B was reduced from 291.84 +/- 28.97 mg/dl to 224.5 +/- 47.11 mg/dl at 6 and 12 months respectively, without significant modifications of other lipidic parameters and without adverse events. LDL-apheresis is a therapeutic approach effective in the reduction of total plasmatic cholesterol, in conjunction with to LDL and APO B in patients refractory to lipid lowering agents.